𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Histochemical assay of estrogen and progesterone receptors in breast cancer: Correlation with biochemical assays and patients' response to endocrine therapies

✍ Scribed by Louis P. Pertschuk; Ellis H. Tobin; Eric Gaetjens; Anne C. Carter; George A. Degenshein; Norman D. Bloom; David J. Brigati

Publisher
John Wiley and Sons
Year
1980
Tongue
English
Weight
697 KB
Volume
46
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Estrogen (ER) and progesterone (PgR) receptors were assayed by histochemistry in primary, recurrent, and metastatic breast cancer. Ligand-conjugates composed of 17P-estradiol and 1 lcu-hydroxyprogesterone covalently linked to bovine serum albumin and labelled with fluorescein isothiocyanate were employed. Results were compared with those of conventional biochemical receptor assays and correlated for ER in 92% of 314 tumors and for PgR in 86% of 86 specimens. ER and PgR determinations by both assay systems were correlated with clinical response to various endocrine therapies in 40 women with Stage 1V disease. The histochemical assay enabled successful prediction of response in 80% of cases including eight which could not be fully analyzed biochemically.

Cancer 46:2896-2901, 1980.

HE VALUE OF ESTROGEN (ER) and progesterone

T (PgR) receptors in predicting clinical response to additive or ablative endocrine treatment of patients with mammary carcinoma is now well e~tablished.'-~ Current biochemical steroid hormone receptor assays, however, are difficult to perform. These assays are expensive and require radiolabelled ligands and sophisticated monitoring equipment. Tissue homogenization is necessary for the detection of cytosol or nuclear receptor. As a consequence, there is an admixture of all tissue components. This disruption of the specimen

πŸ“œ SIMILAR VOLUMES

Estrogen and progesterone receptors in t
Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy
✍ Andrea Manni; Baha'Uddin Arafah; Olof H. Pearson πŸ“‚ Article πŸ“… 1980 πŸ› John Wiley and Sons 🌐 English βš– 302 KB πŸ‘ 2 views

This review presents our experience with the use of estrogen receptors (ER) and progesterone receptors (PgR) in the prediction of response to endocrine therapy in stage IV breast cancer. Presence of ER (>3 fmoUmg cytosol protein) significantly predicted response to the antiestrogen tamoxifen and to

Estrogen receptor (ER) and progesterone
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study
✍ Richard M. Elledge; Stephanie Green; Reginald Pugh; D. Craig Allred; Gary M. Cla πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 133 KB πŸ‘ 2 views

Results of estrogen receptor (ER) and progesterone receptor (PgR) ligand-binding assays (LBAs) are strongly correlated with ER and PgR by immuno-histochemistry (IHC). To investigate whether ER and PgR by IHC are also strongly correlated with tamoxifen response, time to treatment failure (TTF) and ov

The use of molecular assays to establish
The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy
✍ Frank A. Vicini; J. Vito Antonucci; Neal Goldstein; Michelle Wallace; Larry Kest πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 100 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Results from numerous trials have indicated that breast‐conserving therapy (BCT) produces outcomes equivalent to those produced by mastectomy in terms of both locoregional control and survival. However, conservative treatment has resulted in the dilemma of how best to ad